Immunogenicity of therapeutic recombinant immunotoxins
Authors:
- 10 February 2016
- journal article
- review article
- Published by Wiley in Immunological Reviews
- Vol. 270 (1) , 152-164
Abstract
Summary: Recombinant immunotoxins (RITs) are chimeric proteins designed to treat cancer. They are made up of an Fv or Fab that targets an antigen on a cancer cell fused to a 38‐kDa portion of Pseudomonas exotoxin A (PE38). Because PE38 is a bacterial protein, it is highly immunogenic in patients with solid tumors that have normal immune systems, but much less immunogenic in patients with hematologic malignancies where the immune system is suppressed. RITs have shown efficacy in refractory hairy cell leukemia and in some children with acute lymphoblastic leukemia, but have been much less effective in solid tumors, because neutralizing antibodies develop and prevent additional treatment cycles. In this paper we will (i) review data from clinical trials describing the immunogenicity of PE38 in different patient populations; (ii) review results from clinical trials using different immunosuppressive drugs; and (iii) describe our efforts to make new less‐immunogenic RITs by identifying and removing T‐ and B‐cell epitopes to hide the RIT from the immune system.Keywords
Funding Information
- National Cancer Institute
This publication has 88 references indexed in Scilit:
- Shaping T Cell – B Cell Collaboration in the Response to Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp120 by Peptide PrimingPLOS ONE, 2013
- Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based onPseudomonasexotoxin AProceedings of the National Academy of Sciences, 2012
- Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopesProceedings of the National Academy of Sciences, 2012
- Antibody-Based Immunotoxins for the Treatment of CancerAntibodies, 2012
- Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivoClinical Immunology, 2012
- A guide to taming a toxin – recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancerThe FEBS Journal, 2011
- Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopesProceedings of the National Academy of Sciences, 2011
- Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral driftProceedings of the National Academy of Sciences, 2011
- Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics☆Advanced Drug Delivery Reviews, 2009
- An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopesProceedings of the National Academy of Sciences, 2008